This comprehensive analysis reveals that the synergistic effect of Abi and Prog in combating GBM involves a multifaceted approach, including the inhibition of glucose metabolism and the modulation of CDK1 activity, providing a clearer understanding of their potential as a combined therapy in GBM treatment. Here, CDK1 is linked to glioblastoma.